SB Avandia, Takeda/Lilly Actos Antidiabetics Set For Advisory Cmte. Review
Executive Summary
SmithKline Beecham's Avandia and Takeda/Lilly's Actos have been scheduled for review by an FDA advisory committee one month after the agency plans to discuss the safety of the first "glitazone" insulin sensitizer Rezulin.